Pulse Biosciences

Update in progress

PLSE (NasdaqCM)

Company RatingNeutral
SectorHealthcare
IndustryMedical Instruments & Supplies

Pulse Biosciences, Inc. is a bioelectric medicine company that develops and commercializes the nPulse platform for ablation. Its offerings include the nPulse System for skin lesions, the nPulse Vybrance Percutaneous Electrode for soft tissue ablation, the nPulse Cardiac Surgical Clamp for atrial fibrillation procedures, the nPulse Cardiac Catheter for circular ablation, and the nPulse Console to support clinical workflows. Formerly Electroblate, Inc., it was renamed in 2015 and was founded in 2014, based in Miami, Florida.

Company score

Sentiment: 0.42; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.21; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.15; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.10; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.26; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive